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The Ptdlns-3-kinase (PI3-K) signaling pathway plays a vital role in cell survival, proliferation, apoptosis
and differentiation in normal cells, as well as in diseases such as cancer and diabetes. Quantiﬁcation
of phospho-Akt is a standard way of assessing the activity of the PI3-K signaling pathway in both cells
and tumors. This measurement is traditionally performed semiquantitatively using immunoassays such
as Western blot. Here we report an LC-MS method to accurately measure the stoichiometry of Akt
phosphorylation in biological samples. The procedure includes immunoprecipitation, gel electrophoresis,
in-gel digestion, addition of isotopicaly labeled internal standards and LC-MS/MS. Two proteolytic
enzymes, chymotrypsin and trypsin, were used to generate suitable peptide fragments for measuring
Thr308 and Ser473 phosphorylation, respectively. The interday imprecision was estimated to be 3.8%
and 2.3% for Thr308 and Ser473, respectively. This method has been tested on human T-cells grown
in presence and absence of pervanadate and with or without a PI3-K inhibitor and on human
glioblastoma cells (U-87 MG) grown in presence and absence of wortmannin (PI3-K inhibitor).The results
of T cells suggest that the levels of Akt phosphorylation in untreated cells were below 1% for both
phosphorylation sites. Pervanadate treatment provoked an 18-fold increase in phosphorylation of Thr308
and the PI3-K inhibitor partially reversed the increase. A comparison between LC-MS/MS and Western
blotting suggests that the LC-MS based method is of comparable sensitivity and provides a more
accurate phosphorylation stoichiometry, a wider dynamic range and more in-depth information. The
application of the new method and its utility to providing predictive markers of response to targeted
therapies is discussed.
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Introduction
The phosphatidylinositol-3-kinase (PI3-K) pathway, one of
the signaling pathways downstream of receptor tyrosine ki-
nases, controls a wide range of biological processes including
survival, cell proliferation,
1,2 metabolism
3,4 and cell mobility.
3
Activation of PI3-K pathway involves growth factor binding to
a receptor tyrosine kinase and activation of PI3-K, which
phosphorylates membrane-bound phosphatidylinositol biphos-
phate, (PIP2) to generate phosphatidylinositol trisphosphate
(PIP3). It is believed that, upon binding of PIP3 to the pleckstrin
homology (PH) domain, the phosphoinositide dependent
protein kinases PDK-1 is recruited to the plasma membrane
and become activated although the degree of recruitment
remains controversial.
5 PDK1 was discovered a decade ago
6 and
is known to transduce signals by phosphorylating and activat-
ing a number of downstream protein kinases such as Akt/PKB,
SGK, PKCzeta, PKCdelta, p70 S6 kinase, p90 ribosomal S6
kinase (p90 Rsk) and p21-activated kinase (see ref 7 for review).
The identity of PDK2 has been controversial with various
kinases proposed to act as the PDK-2 for Akt, such as ILK and
PKC. However, recent biochemical studies have strongly sug-
gested that PDK-2 is the mTOR/Rictor complex.
8 The activity
of the PI3-K pathway is negatively regulated by the lipid
phosphatases PTEN and SHIP.
9,10
Akt/PKB is a critical component in the PI3-K pathway
residing directly downstream of both PDK-1 and -2.
5 There are
three Akt protein kinase isoforms (Akt 1, 2, 3) showing a high
degree of sequence homology, but differences in location of
expression in mammals.
11,12 Akt1 is the predominant isoform
in most tissues, Akt2 is highly expressed in the insulin-
responsive tissues, and Akt3 is abundant in brain.
13 Each Akt
isoform has three functionally distinct domains: an N-terminal
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Activation of Akt is regulated through two distinct phospho-
rylation events at Thr308 and Ser473 in Akt1, 309 in Akt2 and
305 in Akt3. Phosphorylation of Thr308, which precedes Ser473,
is mediated by PDK-1 and is sufﬁcient to activate Akt. However,
phosphorylation at both sites is required for maximal activation
of this phosphoprotein. Phosphorylation of Thr308 by PDK-1
is believed to render the Ser473 site accessible to PDK-2.
14
These two phosphorylation events are often used as indicators
for PI3-K pathway activation.
The PI3-K pathway is also found to be deregulated in many
diseases such as cancer and diabetes. For example, overacti-
vated PI3-K is found in 32% of colon, 27% of glioblastoma, 25%
of gastric and 8% of breast cancers.
15 The overactivation of such
a pathway could be caused by mutations, ampliﬁcation/
overexpression of key components in the pathway or through
inactivation of tumor suppressor protein PTEN.
16,17 In diabetes,
the compromised insulin signaling pathway which includes
PI3-K/mTOR pathway has been implicated in causing insulin
resistance in tissues and   cell dysfunction in pancreas.
18,19
Because of its importance in physiological and pathological
conditions, measurement of PI3-K activation has became an
essential task for scientists in cell biology and biomedical
research.
Conventionally, detection of PI3-K pathway activation is
performed by measuring phosphorylation at Thr308 and Ser473
on Akt using immunoassays such as Western blot, or less
frequently by a kinase activity assay (either PI3-K itself or its
downstream kinase such as Akt). The latter provides most direct
activity measurements but requires fresh samples making it
less applicable to clinical samples. The former estimates Akt
phosphorylation by the ratio of signals from two immunoas-
says: one using phospho-speciﬁc antibody and the other total
Akt antibody. Despite being very sensitive, this method provides
only arbitrary ratios and a reference control sample to which
the comparison of the levels of phosphorylation in experimental
samples is required. Without absolute stoichiometry readings,
critical information is missed. In the case of PTEN mutation,
although it is known that PTEN knockout causes tumorigenesis
via activation of Akt (for review, see ref 20), the quantity of Akt
and the stoichiometries of phosphorylation at Thr308 and
Ser478 that are required to trigger such an event are unknown.
Quantitative information about the total amount of Akt and
its phosphorylation stoichiometry could be used not only to
understand the biological roles of Akt, but also to assess the
effectiveness and/or appropriate dosing of PI3-K inhibitors in
cancer patients. The other advantage of absolute quantiﬁcation
of phosphorylation stoichiometry is that data from different
studies can be directly compared, and thus, population studies
with large sample sizes can be conducted.
A relatively new strategy of quantifying phosphorylation
using LC-MS has been proposed by Gygi and his colleagues.
21
The procedure consists of immunoprecipitation, SDS-PAGE,
protease digestion, internal standard spike-in, and LC-MS/MS.
This method utilizes a synthetic peptide with incorporated
stable isotopes as ideal internal standards to mimic native
peptides formed by proteolysis. The internal standard peptide
is then used to quantitatively measure the absolute levels of
proteins and post-translationally modiﬁed proteins after pro-
teolysis by using triple quadrupole tandem mass spectrometer
in multiple reaction monitoring (MRM) mode. This approach
has been used to monitor phosphorylation events in human
separase protein,
21 focal adhesion kinase,
22,23 cyclin-dependent
kinases,
24 ERK and S6 kinase.
25 In this study, we adapted the
same approach to measure and monitor the phosphorylation
stoichiometry of Akt in both T and U-87 MG cells grown in
various conditions. The assay performance was assessed
extensively.
Experimental Procedures
Cell Culture, Immunoprecipitation of Akt, and
SDS-PAGE. Human CD8 activated T-cells were isolated and
puriﬁed from the peripheral blood mononuclear leucocytes.
26
Isolated T-cells were activated with 2 µg/mL phytohemagglu-
tinin and cultured in RPMI medium for 3 days. The cells were
then washed and subcultured in RPMI supplemented with 10%
fetal calf serum (FCS) in presence of IL2 (20 ng/mL) every 3
days until reaching conﬂuency (2 × 106 cell/mL). Prior to
treatments, cells were washed with PBS, resuspended in fresh
RPMI at 108 cell/mL and then divided equally into four separate
treatment groups consisting of the control, PI3-K inhibitor
alone (treatment with 10 µM of PI3-K inhibitor LY294002 for
35 min), PI3-K inhibitor LY294002 and pervanadate (100 µM),
and pervanadate (100 µM) alone. Incubation in presence of
pervanadate was carried out for 12 min.
T-cells were subsequently harvested by centrifugation (108
cells, for each phosphorylation site), washed twice with PBS
and then lysed in 2 mL of lysis buffer (50 mM Tris-HCl, pH
7.4, 2 mM EDTA, 1% NP40, 5 mM sodium pyrophosphate
decahydrate (Sigma), 5 mM  -glycerol 2-phosphate disodium
salt hydrate (Sigma), 5 mM sodium pervanadate, protease
inhibitor cocktail (Roche), and phosphatase inhibitor cocktail
(Calbiochem)). Lysed cells were left on ice for 10 min with
regular vortexing for 10 s every 2 min. Insoluble material was
removed by centrifugation 10 min at 13 000g. The cell lysate
was centrifuged again for 2 min to remove residual insoluble
material. Seven micrograms of rabbit polyclonal anti-Akt1
antibody (Millipore) bound to protein G agarose beads (60 µL
of 50% slurry) was added to the clear lysate. The mixture was
left at 4 °Cf o r2ho nashaking platform and beads were
subsequently washed 5 times in 500 µL of wash buffer (lysis
buffer supplemented with 200 mM NaCl) to remove nonspe-
ciﬁcally bound proteins. Ten microliters of 4× loading buffer
(Invitrogen) and 5 µL of 50 mM DTT were then added to the
beads followed by incubation at 70 °C to reduce cysteine
residues. Alkylation was performed by adding 5 µL of 300 mM
iodoacetamide (Sigma) and incubation at room temperature
in the dark for 30 min. Proteins were separated on a NuPAGE
bis-tris 4-12% gradient gel (Invitrogen) at 200 V for 45 min
and gels were washed for 5 min in Milli-Q water before staining
with 20 mL of Simply Blue (Invitrogen) to visualize proteins.
The gel was subsequently washed with Milli-Q water four times
over 10 h.
For the U-87 MG (American Type Culture Collection) experi-
ments, cells were grown in DMEM medium supplemented with
10% FCS in a humidiﬁed atmosphere of 95% air and 5% CO2
at 37 °C. The medium was changed every second day and cells
were subcultured every 3 to 4 days when they reached 80-90%
conﬂuency. U-87 MG cells were grown in the presence or
absence of 7 nM wortmannin for2ht oevaluate the effect of
the PI-3K inhibitor on Akt phosphorylation. About 3 × 107 cells
in each group were used to measure each phosphorylation site.
Cell lysis, immunoprecipitation and SDS-PAGE were performed
as described above for T cells.
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procedure followed was previously described
27 with some
modiﬁcations. The Akt protein band was cut with a clean
scalpel blade, transferred to a microcentrifuge tube and cut
into small pieces. Gel pieces are washed for 15 min sequentially
with 200 µL of Milli-Q water, 200 µL of acetonitrile, 200 µLo f
100 mM ammonium bicarbonate, 200 µL 20 mM ammonium
bicarbonate and 50% acetonitrile and ﬁnally 100 µL of aceto-
nitrile. The gel pieces were then air-dried in a laminar ﬂow.
In-gel digestion was carried out with trypsin (measurement
of phosphorylation at Ser473 site) or chymotrypsin (measure-
ment of phosphorylation at Thr308) at a ﬁnal concentration of
12 µg/mL (in 30 mM ammonium bicarbonate). Heavy peptides
(Cambridge Research Bioscience, Cambridge, U.K.) corre-
sponding to the phospopeptide and nonphosphopeptide of
both sites were spiked-in at a ﬁnal amount of 37 fmol. After
overnight incubation (∼16 h) on a shaker at 37 °C, an equal
volume of acetonitrile (i.e., 30 µL) was added and the peptide
mixtures were extracted by shaking (1000 rpm) at room
temperature for 10 min. The resulting supernatant was trans-
ferred to a fresh microcentrifuge tube. Peptides in the gel pieces
were further extracted ﬁrst by adding 50 µL of 5% formic acid
and shaking for 20 min then 50 µL of 100% acetonitrile for
another 20 min. The supernatant was then collected and
transferred to the ﬁrst fraction. The gel pieces were ﬁnally
washed with 50 µL of acetonitrile for 10 min and the three
pooled fractions were dried in Speed-Vac and stored at -70 °C
until further processing.
Alkylation of Thr308 and Phospho-Thr308 Peptides. The
peptides used for quantiﬁcation of the phosphorylation site
Thr308 contain a cysteine residue which required reduction
and alkylation. This was achieved by adding 10 µLo f1 0m M
DTT to 10 µL of light or heavy peptides (both phospho- or
nonphosphopetides, 1 nM) and incubation at room tempera-
ture for 45 min with regular sonication every 15 min. A total of
2.5 µL of ammonium bicarbonate (1.0 M) was then added to
the sample prior to the incubation at 60 °C for 1 h. After cooling
to room temperature, 4.5 µL of iodoacetamide (300 mM) was
added to the samples and the mixture was incubated at room
temperature in the dark on an orbital shaker for 1 h. Three
microliters DTT (100 mM) was added to the samples followed
by the addition of 20 µL of 5% formic acid and 140 µL of Milli-Q
water.
LC/MS Conditions. Quantiﬁcation of Akt peptides (and
phospho-peptides) was performed by LC-MS on a Q-TRAP 4000
(ABI-MDS-Sciex) mass spectrometer coupled with a Dionex
3000 nano-LC system. LC buffers were the following: buffer A
(2% acetonitrile and 0.1% formic acid in Milli-Q water (v/v))
and buffer B (90% acetonitrile and 0.08% formic acid in Milli-Q
water (v/v). Peptide mixtures were reconstituted in 54 µLo f
0.5% formic acid and then pipetted into microvials containing
1 µL of 25 mM EDTA. Aliquots of 16 µL of each sample were
loaded at 20 µL/min onto a trap column (300 µm × 5 mm,
PepMap C18 column, 5 µm, 100 Å, LC packing) equilibrated in
99% buffer A. The trap column was washed for 4 min at the
same ﬂow rate and then the trap column was switched in-line
with an LC-Packings, resolving C18 column (300 µm × 15 mm,
PepMap C18 column, 3 µm, 100 Å, LC-Packings). The peptides
were eluted from the column at a constant ﬂow rate of 300
nL/min with a linear gradient from 99% buffer A to 45% buffer
B in 20 min, then to 90% buffer B by 22 min. The column was
then washed with 90% buffer B for 10 min and re-equilibrated
in 99% buffer A. The HPLC was interfaced to the mass
spectrometer with an FS360-20-10 picotip (New Objectives)
ﬁtted to a NanoSpray II Source and interface kit (Applied
Biosystems). The Q-trap 4000 was operated in the positive
mode using MRM mode with analyte and source dependent
parameters that were optimized for each peptide and MRM
transition (Table 1).
Western Blotting. The same amount of proteins (e.g., 20 µg)
from each group of cultured cells and 12.2 ng of recombinant
Akt (Millipore) as control were subjected to gel-electrophoresis
(NuPAGE Bis-Tris 4-12% gradient gel). After electrophoresis,
proteins were transferred onto PVDF membrane (Invitrogen)
a t2 5m Af o r2ha troom temperature using X Cell Sure Lock
and Blot module (Invitrogen). After blocking overnight in Buffer
C (PBS containing 4% BSA and 0.5% Tween 20) at 4 °C,
membranes were incubated with primary antibody (anti-
phospho-Akt, Thr308 (Cell Signaling) diluted 1/500, anti-
phospho-Akt Ser473 (Cell Signaling) diluted 1/1000 or total anti-
Akt antibody (Millipore) diluted 1/1000 in Buffer C for4ha t
room temperature. Loading was conﬁrmed using anti-Actin
antibody (Santa Cruz) diluted 1/1000 in buffer C. Membranes
were washed three times for 5 min in Buffer C and then
incubated for1ha troom temperature with secondary antibody
(stabilized goat anti-rabbit or anti-mouse conjugated to horse-
radish peroxidase (HRP), Pierce) diluted 1/600 in buffer C.
Visualization was by enhanced chemiluminescence (GE Bio-
sciences).
Data Analysis. Data analysis was performed using Microsoft
Excel (Version 2003, Microsoft) or Analyst software (Version 1.4,
Applied Biosystems). Peak areas for the phospho- and non-
phospho peptides from both phosphorylation sites were cal-
culated for the dominant MRM transition of each peptide. The
equation used for quantitation of peptide of interest is the
following. Quantity of peptide of interest ) (peak area of
transition representing peptide of interest)/(peak area of transi-
tion representing the Internal standard (IS)) × the quantity of
IS. Percentage of phosphorylation was calculated as (phospho
peptide)/(phospho peptide + nonphospho peptide) × 100.
Table 1. Sequences, Molecular Weight (MW), Retention Times, Charge States, and Transitions of 8 Peptides Used for the
Quantiﬁcation of Akt Phosphorylation at Thr308 and Ser473
peptide sequence MW retention time (min) charge state transition collision energy
Phospho-Thr308 GLCKEGIKDGATMK[pT]F 1835.8 14.7 [M + 3H]3+ 612.6 f 745.4 27
Phospho-Thr308 (IS) GLCKEGIKDGATM[KC13N15][pT]F 1843.8 14.7 [M + 3H]3+ 615.2 f 749.4 28
Nonphospho-Thr308 GLCKEGIKDGATMKTF 1755.8 14.1 [M + 3H]3+ 585.9 f 745.4 27
Nonphospho-Thr308 (IS) GLCKEGIKDGATMK[C13N15]TF 1763.8 14.1 [M + 3H]3+ 588.6 f 749.4 27
Phospho-Ser473 RPHFPQFSY[pS]ASGTA 1732.7 17.3 [M + 2H]2+ 866.8 f 254.2 47
Phospho-Ser473 (IS) RPHFPQ[FC13N15]SY[pS]ASGTA 1742.7 17.3 [M + 2H]2+ 871.8 f 254.2 47
Nonphospho-Ser473 RPHFPQFSYSASGTA 1652.7 16.0 [M + 2H]2+ 826.8 f 254.2 46
Nonphospho-Ser473 (IS) RPHFPQ[FC13N15]SYSASGTA 1662.7 16.0 [M + 2H]2+ 831.8 f 254.2 46
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Workﬂow of LC-MS Based Quantiﬁcation. The procedure
of MRM-based quantitative analysis is shown in Figure 1A and
is primarily based on the workﬂow published by Gygi and
colleagues.
21 In brief, after cells or tissues lysis, Akt was
immunoprecipitated from the lysate and the precipitated
proteins were then reduced and alkylated (to eliminate disulﬁde
bridges and hence cross-linked peptides) before SDS-PAGE
protein separation. The Akt band was excised, washed and
mixed with heavy isotope internal standards corresponding to
the peptides and phosphopeptides of interest. Enzymatic
digestion was then carried out prior to LC-MS/MS using the
MRM mode. Before the levels of phosphorylated and nonphos-
phorylated peptides can be measured in samples, several assay
development steps including selection of protein digestion
method and immunoprecipitation were optimized. The former
is particularly important as it also determines the characteristics
(i.e., length and amino acid composition) of the resultant
peptides to be analyzed and quantiﬁed.
In silico digestion of the Akt amino acid sequence with
various proteolytic enzymes suggested that Asp-N might
generate suitable peptide fragments for measuring both the
Thr308 and Ser473 phosphorylation sites. However, subse-
quent trials using recombinant Akt, Asp-N and LC-MS/MS
analysis showed that only the peptide containing Ser473, and
not that containing Thr308, was detected (data not shown).
As an alternative, trypsin and chymotrysin were chosen to
digest Akt into peptide fragments for monitoring phospho-
rylation at the Ser473 and Thr308 sites, respectively. Both
phospho- and nonphospho-peptides (phospho-Thr308 and
Thr308; phospho-Ser473 and Ser473) generated, respectively,
by chymotrypsin and trypsin digestion of recombinant Akt,
can be detected (Figure 1B).
Characterization of AQUA Peptides Using LC-MS/MS. To
quantify the levels of Thr308, phospho-Thr308, Ser473 and
phospho-Ser473 peptides, a total of eight peptides (isotopic
heavy and light peptide for each site) were synthesized. These
peptides were also used to optimize conditions for both LC
separation and MS detection. The retention time, MRM transi-
tion, and major settings in LC-MS are summarized in Table 1.
Phosphopeptides are retained longer on the column than their
unmodiﬁed counterparts (Figure 1B). The standard curve of
phospho-Ser473 peptide showed linearity in the range of
0.05-500 fmol (Figure 2A). The lower limits of detection for
the eight peptides were around 40-120 amol, as deﬁned by
signal-to-noise ratios >5 (Figure 2B). The lower limits of
quantiﬁcation were between 90-250 amol, as determined by
intra- and interassay imprecision and inaccuracy <25% (Figure
2B).
Selection of Suitable Immunoprecipitation Antibody. An
immunoprecipitation step is normally required to detect low-
abundance proteins such as Akt. The immunoprecipitation
enriches protein-of-interest and improves the sensitivity of LC-
MS/MS methods. Three antibodies (7 µg) recognizing three
different parts (a.a. 1-149, mouse monoclonal anti Akt-1,
(Millipore), a.a. 140-480, mouse monoclonal anti-Akt1, (Cell
Signaling) and a.a. 466-480, rabbit polyclonal anti-Akt1, (Mil-
lipore)) of Akt1 were tested for their ability to immunoprecipi-
tate 0.2 µg of the active form of recombinant Akt1. The results
suggest that the antibodies recognizing a.a. 140-480 and a.a.
466-480 gave the best recovery (∼80%) (Supplementary Figure
S1). The antibody preparation recognizing a.a. 140-480 con-
tained an interfering protein that migrated close to the
recombinant Akt1 band on SDS-PAGE and therefore was not
considered for further use. The efﬁciency of immunoprecipi-
tation using this antibody was also tested on T cells cultured
in the presence or absence of pervanadate in order to examine
the ability of pool-down for both phosphorylated and unphos-
phorylated forms of Akt. The results showed that this antibody
pooled down quantitatively both phosphorylated and un-
phoshorylated (or low phosphorylated) forms of Akt1 (Supple-
mentary Figure S2). Thus, the antibody recognizing the C-terminal
region of Akt1 (a.a. 466-480) was used for immunoprecipitation
of Akt1 from biological samples throughout the study.
Effects of Methionine Oxidation and the Cysteine
Alkylation Step on Thr308 Phosphorylation Measurements.
The Thr308 and phospho-Thr308 peptides contain a methion-
ine residue at position 306 prone to oxidation by free radicals,
and a cysteine residue requiring alkylation to prevent cross-
linking (Table 1). These processes could potentially cause
discrepancies in the measurement of these peptides. LC-MS/
MS analysis of chymotrypsin digested recombinant Akt after
SDS-PAGE indicates that both unoxidized and oxidized forms
were observed for the phospho-Thr308 peptide and the Thr308
peptides using a data dependent MS/MS acquisition method
and also using MRM mode taking into account the extra 16
Da mass shift resulting from methionine oxidation. Both
Figure 1. Assay procedure of LC-MS-based quantiﬁcation of Akt
phosphorylation stoichiometry at Thr308 and Thr473. (A) The
procedure for LC-MS based phosphorylation measurement con-
tains six steps including lysis of cell/tissue, immunoprecipitation,
reduction/alkylation, proteolytic digestion, and LC-MS/MS. (B)
Representative MRM extracted ion chromatogram for Thr308,
phospho-Thr308, Ser473 and phospho-Ser473 peptides. Phos-
phopeptides are shown in red.
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in accordance with their polar character (Figure 3A). Methion-
ine oxidation of both Thr308 and phospho-Thr308 was also
conﬁrmed by Mascot database search (Figure 3B).
To examine the inﬂuence of potential oxidation of methion-
ine and the alkylation step on the measurement of Akt
phosphoryaltion at Thr308, the assay was performed 5 times
(3 replicates each time) on different days using recombinant
Akt protein (0.2 µg) and the interday imprecision was estimated.
We found that the imprecisions for the absolute quantiﬁcation
of unoxidized Thr308 peptide and phospho-Thr308 peptide
were 28% and 32%, respectively, which are signiﬁcantly higher
than those of Ser473 and phospho-Ser473 (14.2% and 14.0%,
respectively, Table 2). These results imply that oxidation of
methionine and the alkylation step increase imprecision for
measuring the absolute quantities of the Thr308 and phospho-
Thr308 peptides. Nevertheless, the ratio of phospho-Thr308 to
Thr308 was reliable, as indicated by the interday imprecision
of only 3.8%. The active form of human recombinant Akt1 was
used as a quality control sample for all measurements. The
levels of phosphorylation at Thr308 and Ser473 sites in the
recombinant Akt1 were found to be 78.1 ( 3.0% and 82.2 (
1.9%, respectively (mean ( SD) (Table 2). These ratios did not
change when other buffer systems (e.g., 80% acetonitrile and
50% methanol) were used, suggesting that the phospho- and
nonphospho-peptides behave similarly during protein digestion
and extraction.
Stoichiometry of Akt Phosphorylation in Human T-Cells
and the Effects of Pervanadate and PI-3 Kinase Inhibitor
Treatment. A human T-cell model with pervanadate and /or
PI-3 kinase inhibitor treatments was used to test if the LC-MS/
MS method can be used to measure Akt phosphorylation
stoichiometry in biological samples. Pervanadate, an extremely
potent protein-tyrosine phosphatase inhibitor,
28 is known to
activate the PI-3K pathway and stimulate phosphorylation of
Akt.
29,30 Human CD8+ T-cells (2 × 108 cells) from healthy
volunteers were cultured in the absence or presence of per-
vanadate for 15 min with and without a PI3-K inhibitor
(LY294002). The stoichiometry of Akt1 phosphorylation was
monitored using both the LC-MS/MS method and traditional
Western blotting.
Western blotting analysis indicated that pervanadate stimu-
lated substantial, but undeﬁned, Akt phosphorylation at Thr308
and Ser473 phosphorylation sites compared to the unstimu-
lated cells (Figure 4A). However, the presence of LY294002
decreased phosphorylation levels in both pervanadate stimu-
lated cells and unstimulated cells (Figure 4A). The levels of total
Akt1, which did not show any signiﬁcant difference in all
various treatments, provide a reference point to normalize the
phosphorylation signals. Useful, but ultimately arbitrary, semi-
Figure 2. Analytical performance of LC-MS based quantiﬁcation of Akt phosphorylation stoichiometry at Thr308 and Thr473. (A) An
example of calibration curves for phospho-Ser473 peptide indicates a good linearity over a range between 50 amol and 500 fmol. The
detection limit (deﬁned as signal-to-noise ratio ) 5) is 50 amol for this peptide (bottom left). (B) Summary of analytical performance
of the four peptides measured. Limit of quantiﬁcation (LOQ) is deﬁned as e25% CV and bias for all intraday and interday precision and
accuracy.
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phorylation Western blot signals as a percentage of the signal
for total Akt. In this case, the phosphorylation status for Thr308
and Ser473 in the unstimulated and LY294002 treated cells were
undetectable, making any estimates of fold-change upon
pervanadate treatment impossible (Figure 4A). In the presence
of pervanadate, the PI-3K inhibitor LY294002 decreased Akt
phosphorylation by approximately 55% and 32% for Thr308 and
Ser473, respectively (Figure 4A). The same samples from these
experiments were also analyzed by the LC-MS based method.
We found that in the untreated cells the basal stoichiometry
of Thr308 and Ser473 phosphorylation was just 0.92% and
0.62%, respectively, and that pervanadate treatment provoked
a 39- and 18-fold increase of phosphorylation at Thr308 and
Ser473, respectively (Figure 4B,C). The presence of the PI-3
kinase inhibitor LY294002 decreased phosphorylation at both
sites by ∼30% in the pervanadate stimulated T-cells (Figure
4C). In the untreated T-cells, the presence of LY294002 also
decreased the phosphorylation of Thr308 and Ser473 by 22%
and 47%, respectively (Figure 4C). In these experiments, the
LC-MS method showed signiﬁcant advantages over Western
blotting procedure. Speciﬁcally, the LC-MS method uniquely
allowed the accurate measurement of basal Akt phosphoryla-
tion stoichiometries of the two key phosphorylation sites, their
Figure 3. Oxidation of the methionine residues of the phospho-Thr308 and Thr308 peptides during sample processing. Recombinant
Akt (0.2 µg) was processed through the assay procedures as described in Figure 1 and the resulting peptide mixture was subjected to
LC-MS/MS using an extra transition that takes into account the 16 Da of methionine oxidation. (A) The potential oxidized form (+8,
doubly charged ion) of the Thr308 peptide can be observed (upper panel, blue trace). The oxidized peptide was eluted 2 to 3 min
earlier than its native counterpart in accordance with its polar character. (B) Mascot database search indicates that the oxidized forms
of both Thr308 and phospho-Thr308 can be observed.













1 93.8 30.8 75.3% 176.9 46.4 79.2%
2 115.6 26.9 81.1% 147.5 31.8 82.3%
3 49.3 15.9 75.6% 184.9 37.3 83.2%
4 63.1 18.8 77.0% 168.0 36.5 82.2%
5 86.4 19.8 81.4% 216.8 40.6 84.2%
Average 78.1% 82.2%
SD 3.0% 1.9%
CV 31.9% 27.5% 3.8% 14.2% 14.0% 2.3%
a Measurements are in femtomole of peptide.
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of the pharmacological agent LY294002 on the stoichiometries
of phoshphorylation in resting and stimulated T-cells.
Stoichiometry of Akt Phosphorylation in U-87 MG Cells
and the Effects Wortmannin (PI-3 Kinase Inhibitor)
Treatment. We also compared the LC-MS method with West-
ern blot in U-87 MG cells where the phosphorylation of Akt is
known to be elevated due to the loss of PTEN.
31 Cells were
treated either with or without Ptdlns-3-kinase inhibitor (wort-
mannin) for 2 h prior to lysis. The basal phosphorylation levels
of Akt at Thr308 and Ser473 in U-87 MG cells were 4.80% and
1.49%, respectively, using the LC-MS/MS method (Figure 5A).
The presence of wortmannin resulted in an average reduction
of 28% and 59% in the phosphorylation levels at Thr308 and
Ser473, respectively (Figure 5A). Similarly, Western blots showed
a ∼60% decrease of phosphorylation at Ser473. However, the
decrease was higher at Thr308 (∼60%) compared to the reading
derived from the LC-MS/MS method (Figure 5B).
Discussion
Measurement of protein phosphorylation is typically qualita-
tive or semiquantitative by Western blot using phospho-speciﬁc
antibodies. Consequently, one usually only knows whether the
phosphorylation status of a speciﬁc site in a given protein
component of a signaling cascade has gone up or down in
response to extracellular stimuli. This approach usually does
not indicate the absolute quantity of the protein or the precise
stiochiometry of phosphorylation at speciﬁc sites. This missing
Figure 4. Measurements of phosphorylation stoichiometry of Akt in cultured human T-cells. CD8+ T-cells (2 × 108 cells) derived from
a healthy volunteer (see Experimental Procedures for the details) were cultured in the absence or presence of the stimulant (100 µM
pervanadate) with/without 10 µM LY294002 and the phosphorylation levels of Akt were monitored using traditional Western blotting
method and the LC-MS/MS method. The experiments were performed three times independently. Similar results were observed in an
independent experiment. (A) Western blotting analysis of T-cells treated with pervanadate or LY294002 using phospho-Thr308, phospho-
Ser473, total Akt and actin antibodies. A total of 60 µg of protein were loaded in each well and recombinant Akt (12.2 ng) was used as
a positive control (shown as R). (B) Extracted ion chromatogram of phospho-Thr308 and Thr308 peptides in control and pervanadate
stimulated T-cells. (C) Stoichiometry of Akt phosphorylation (Thr308 and Ser473) in T-cells cultured in different conditions. Phospho
and non-phospho-peptides for both sites are expressed in fmol. All LC-MS runs were performed in triplicate.
Figure 5. Measurements of phosphorylation stoichiometry of Akt
in U-87 MG cells. Cells (20 million cells) were cultured in the
presence or absence of 7 nM wortmannin for 2 h prior to cell
lysis. Stoichiometry of Akt phosphorylation (Thr308 and Ser473)
were analyzed using LC-MS/MS (A) and Western blotting (B).
Stoichiometry of Akt Phosphorylation research articles
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the cells utilize intracellular machinery to propagate signals.
With the LC-MS based quantiﬁcation method, we are able to
monitor phosphorylation events in a much accurate manner.
In this study, we have demonstrated that phosphorylation
stoichiometry of Akt phosphorylation at Thr308 and Ser473 can
be measured accurately in cells. Our results indicate, for the
ﬁrst time, that at the basal state, only 0.92% of Thr308 and
0.62% of Ser473 of Akt were phosphorylated in human T-cells
as opposed to the subjective claim of “very low” traditionally
quoted by cell biologists. This result suggests that, in resting
T-cells, less than 1% of Akt is activated for executing normal
cellular function, while 99% of the Akt pool is inactive,
presumably reserved to respond to potential extracellular
stimulation. Treatment for 12 min with pervanadate, a potent
tyrosine phosphatase inhibitor, provoked 39- and 18-fold
increase in phosphorylation at Thr308 and Ser473 to 55% and
35%, respectively, suggesting that even under this extreme
condition only about 30-55% of T-cell Akt (but not all) is
activated in the phosophorylation cascade downstream to
receptor tyrosine kinases. Interestingly, the level of phospho-
rylation at Thr308 was higher than that at Ser473 with per-
vanadate treatment. It is generally believed that phosphoryla-
tion of Akt by PDK-2 at Ser473 is required to fully activate Akt
and stabilize its activation state.
14 Thus, our results indicate
that only a maximum of 35% of Akt molecules are in a stable,
fully activated, state after 12 min treatment with pervanadate
in human T-cells. The method was also tested on U-87 MG
cells which are known to be lacking PTEN. Inactivation of PTEN
leads to accumulation of PIP3 which results in an increase in
Akt phosphorylation.
31 Our result demonstrated, for the ﬁrst
time, that even without PTEN, the majority of Akt remains
unphosphoryated at Thr308 and Ser473 and such a low level
of phosphorylation is sufﬁcient to stimulate abnormal cell
proliferation contributing to tumorigenesis. For both Western
blotting and the LC-MS/MS method, the decrease of phospho-
rylation caused by the PI3-K inhibitor was similar at Ser473
(∼60%), while at Thr308, the decrease was less pronounced
using the LC-MS/MS method. This discrepancy may be linked
to oxidation of the methionine residue present in the phospho-
Thr308 and Thr308 peptides (Figure 3).
We encountered complications regarding the quantiﬁcation
of phosphorylation at Thr308 of Akt. The chymotryptic peptide
containing Thr308 also contains two reactive amino acid
residues: methionine and cysteine. The cysteine residue was
handled by reduction and S-alkylation. However, S-alkyl cys-
teine is known to be susceptible to oxidation during sample
processing, especially during gel electrophoresis.
32 Similarly,
and more acutely, methionine oxidation occurs in vivo and/
or during sample preparation and electrophoresis and me-
thionine sulfoxide can be further oxidized irreversibly to
methionine sulfone.
32 We have evaluated these effects by
estimating the intraday imprecision in ﬁve independent experi-
ments. As expected, a lower yield and higher imprecision for
Thr308 and phospho-Thr308 peptides, compared to those of
Ser473 and phospho-Ser473 peptides, were apparent (Table 2
and Figure 4C). For this reason, we only recommend using the
Ser473 ﬁgures for absolute quantiﬁcation of Akt. However,
although signiﬁcant variation was observed at the individual
peptide level, the imprecision in the ratio of phospho-Thr308
to Thr308 was acceptable. Thus, it seems that the oxidation
and phosphorylation status of Akt prior to chymotryptic
digestion does not distort the ratio of the phospho-Thr308 and
Thr308 peptides. It also appears that the two peptides, once
generated, behave similarly with regard to methionine oxida-
tion. From these data, we conclude that the phosphorylation
stoichiometry measurements for Thr308 using this method are
robust.
One potential application of this LC-MS method is for patient
selection and for pharmaco-dynamic measurements for PI-3K/
mTOR pathway inhibition. The major issue with current
immunoassay methods is the lack of absolute quantitative
capability. It is often very difﬁcult to compare results from
different studies (or from different laboratories) due to variation
in methods and references used. This method could potentially
provide more deﬁnitive answer as to whether or not a patient
should receive PI-3K/mTOR inhibitor, and could also offer
crucial information on drug dosage and inhibition of the
targets. Our preliminary data using this procedure allow
measurement of Akt phosphorylation status using approxi-
mately 20 mg of breast tumor tissue (A. Thompson, A. Atrih,
and J. Huang, unpublished data). Although this is more than
what is normally required for immunoassays, one can foresee
that this issue could be improved by new generation of mass
spectrometers with better sensitivity. As the MRM approach
allows monitoring multiple sites (up to 100 transitions at the
same time), this approach can in principle be extended to
monitor multiple phosphorylation sites from multiple proteins
in a single LC-MS/MS run. Once developed, this could open
up a new era for quantitative proteomic analysis in systems
biology by providing phosphorylation stoichiometry at the
pathway level. This would be particularly useful for large-scale
population studies.
In summary, we have developed a reliable LC-MS method
for stoichiometric quantiﬁcation of Akt phosphorylation of
Thr308 and Ser473 sites. Compared to Western blot, the LC-
MS based method provides similar sensitivity but signiﬁcantly
more in-depth information.
Abbreviations: Akt, protein kinase B; PI3-K, phosphoinositide
3-kinases; PIP2, phosphatidylinositol biphosphate; PIP3, phos-
phatidylinositol trisphosphate; PH, pleckstrin homology; PDK-
1, 3-phosphoinositide-dependent protein kinase; SGK, serum
and glucocorticoid inducible kinase, PKC; protein kinase C; ILK,
integrin-linked kinase; mTOR, the mammalian target of rapa-
mycin; PTEN, phosphatase and tensin homologue; SHIP, SH2
domain containing inositol phosphatase; MRM multiple reac-
tion monitoring; ERK, extracellular signal-regulated kinase; IL2,
interleukin 2.
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